04-25-02

APR 2 3 2007 3

Express Mail No.: EL 477 03/5 951 US

5 P

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Soff et al.

Application No.: 09/500,397

Group Art Unit: 1642

Filed: February 8, 2000

Examiner: Minh-Tam B. Davis

For:

METHODS AND COMPOSITIONS

Supervisory Examiner: Anthony C. Caputa

FOR GENERATING

ANGIOSTATIN

Attorney Docket No.: 10561-005

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 & §1.56

RECEIVED

APR 2 9 2002

Assistant Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby direct the Examiner's attention to references DB-DD listed on the attached revised form PTO-1449. A copy of these references are enclosed herewith.

Identification of the listed references is not to be construed an admission of the Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Consequently, Applicant respectfully declines to use form PTO-1449, since this form identifies the references cited therein as "Prior Art." As an alternative, Applicant submits herewith one page of a "revised form PTO 1449" entitled "List of References Cited."

Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

04/26/2002 NMOHAMM1 00000147 161150 09500397

01 FC:126

180.00 CH

NY2 - 1170227.4



Each item of information contained in this information disclosure statement was first cited in copending U.S. Application No. 08/991,761 in an Office Action, dated January 29, 2002 (less than three months prior to the filing of this information disclosure statement). In addition, no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this information disclosure statement.

Pursuant to 37 C.F.R. § 1.97(c), the fee due for the filing of this information disclosure statement is believed to be \$180.00. Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. No other fee is believed to be due. However, if any other fee is required please charge the fee to above-identified deposit account number.

Date: April 23, 2002

Respectfully submitted,

Davrea An Coreversi Reg. No. 30,742 Log Brian C. Damy Reg. No. 48,176 30,742

Laura A. Coruzzi

(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosures